Follicular Lymphoma Specialty Channel

Follicular Lymphoma

Specialty Channel

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma

05/16/2024

Amber Denham

The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

The US Food and Drug...

05/16/2024

Oncology

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...

According to a retrospective...

05/08/2024

Oncology

Quiz

Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma

03/27/2024

True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...

True or False: According to...

03/27/2024

Oncology

FDA Approval

FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma

03/11/2024

Amber Denham

The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.

The FDA granted accelerated...

03/11/2024

Oncology

Quiz

Treating Follicular Lymphoma With Obinutuzumab Immunochemotherapy Versus Rituximab Immunochemotherapy

02/05/2024

What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?

What was the key finding from...

02/05/2024

Oncology

News

Prognostic Value of Minimal Residual Disease Among Previously Untreated Patients With Follicular Lymphoma

02/01/2024

Jordan Kadish

Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.

Minimal residual disease status...

02/01/2024

Oncology

Quiz

Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Alone for R/R FL

01/29/2024

True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...

True or False: Findings from the...

01/29/2024

Oncology

News

Tisagenlecleucel Shows Comparable Efficacy, Superior Safety to Axicabtagene Ciloleucel Among Patients With R/R FL

01/22/2024

Amber Denham

Recent study results suggested tisagenlecleucel was associated with similar efficacy and improved safety outcomes compared with axicabtagene ciloleucel treatment among patients with relapsed/refractory follicular lymphoma.

Recent study results suggested...

01/22/2024

Oncology

News

Mosunetuzumab Yields Clinically Beneficial Outcomes for Patients With Follicular Lymphoma Treated With 3 or More Lines of Therapy

01/19/2024

Jordan Kadish

Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.

Real-world data indicated that...

01/19/2024

Oncology

News

Value of MAP Signature and M7-FLIPI for Identifying Risk and Outcomes for Patients With Follicular Lymphoma

01/15/2024

Jordan Kadish

Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...

Identifying specific gene...

01/15/2024

Oncology

News

Obinutuzumab Immunochemotherapy Yielded Sustained Improvement in Progression-Free Survival vs Rituximab Among Patients With FL

10/03/2023

Jordan Kadish

Final analysis of the phase 3 GALLIUM trial showed a sustained improvement in progression-free survival with obinutuzumab-based immunochemotherapy compared to rituximab-based immunochemotherapy among patients with previously untreated...

Final analysis of the phase 3...

10/03/2023

Oncology

News

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma

05/16/2024

Amber Denham

The US Food and Drug...

05/16/2024

Oncology

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective...

05/08/2024

Oncology

FDA Approval

FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma

03/11/2024

Amber Denham

The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.

The FDA granted accelerated...

03/11/2024

Oncology

News

Prognostic Value of Minimal Residual Disease Among Previously Untreated Patients With Follicular Lymphoma

02/01/2024

Jordan Kadish

Minimal residual disease status...

02/01/2024

Oncology

News

Tisagenlecleucel Shows Comparable Efficacy, Superior Safety to Axicabtagene Ciloleucel Among Patients With R/R FL

01/22/2024

Amber Denham

Recent study results suggested...

01/22/2024

Oncology

News

Mosunetuzumab Yields Clinically Beneficial Outcomes for Patients With Follicular Lymphoma Treated With 3 or More Lines of Therapy

01/19/2024

Jordan Kadish

Real-world data indicated that...

01/19/2024

Oncology

News

Value of MAP Signature and M7-FLIPI for Identifying Risk and Outcomes for Patients With Follicular Lymphoma

01/15/2024

Jordan Kadish

Identifying specific gene...

01/15/2024

Oncology

News

Obinutuzumab Immunochemotherapy Yielded Sustained Improvement in Progression-Free Survival vs Rituximab Among Patients With FL

10/03/2023

Jordan Kadish

Final analysis of the phase 3...

10/03/2023

Oncology

News

Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Monotherapy for Patients With R/R Follicular Lymphoma

09/25/2023

Amber Denham

Zanubrutinib plus obinutuzumab demonstrated a favorable risk/benefit profile compared with obinutuzumab alone among patients with relapsed/refractory FL, according to results from a phase 2 trial.

Zanubrutinib plus obinutuzumab...

09/25/2023

Oncology

News

Prognostic Value of PET Status for Patients With R/R Follicular Lymphoma Undergoing AutoSCT

07/31/2023

Jordan Kadish

Pre-autologous stem cell transplantation positron emission tomography status has strong prognostic value and may help to improve the risk stratification and selection of patients for autoSCT, according to a retrospective analysis.

Pre-autologous stem cell...

07/31/2023

Oncology

Interactive Features

Quiz

Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma

03/27/2024

True or False: According to...

03/27/2024

Oncology

Quiz

Treating Follicular Lymphoma With Obinutuzumab Immunochemotherapy Versus Rituximab Immunochemotherapy

02/05/2024

What was the key finding from...

02/05/2024

Oncology

Quiz

Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Alone for R/R FL

01/29/2024

True or False: Findings from the...

01/29/2024

Oncology

Quiz

Predictive Value of Ki67 Expression for Follicular Lymphoma

08/03/2023

True or False: In a study assessing potential predictive biomarkers for follicular lymphoma, results indicated that high follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma...

True or False: In a study...

08/03/2023

Oncology

Quiz

Subcutaneous Rituximab for Low-Tumor Burden FL

06/07/2023

True or False: In a study assessing the efficacy and safety of subcutaneous rituximab following induction therapy among patients with low-tumor burden follicular lymphoma, high rituximab exposure during the start of treatment was associated...

True or False: In a study...

06/07/2023

Oncology

Quiz

EZH2 Inhibitor PF-06821497 for Follicular Lymphoma

05/30/2023

True or False: In a study assessing the efficacy and safety of EZH2 inhibitor PF-06821497 among patients with follicular lymphoma, the monotherapy expansion dose was determined to be 75-625 mg twice daily.

True or False: In a study...

05/30/2023

Oncology

Quiz

Quiz: Linperlisib for R/R Follicular Lymphoma

04/25/2023

A study assessing the efficacy and safety of linperlisib for the treatment of relapsed/refractory follicular lymphoma found that patients who received this oral PI3Kδ inhibitor reached an overall response rate of ___.

A study assessing the efficacy...

04/25/2023

Oncology

Quiz

Quiz: Odronextamab Plus Optimized Step-Up Regimen for Follicular Lymphoma

03/31/2023

Patients with R/R follicular lymphoma grade 1 to 3a who received odronextamab plus an optimized step-up regimen reached an overall response of ___.

Patients with R/R follicular...

03/31/2023

Oncology

Quiz

Quiz: Complete Response Rate of Obinutuzumab Plus Lenalidomide For Patients with Follicular Lymphoma

11/09/2022

Obinutuzumab plus lenalidomide demonstrated promising efficacy and safety among patients with previously untreated advanced follicular lymphoma in a recent phase 2 trial, with a primary end point of complete response rate after induction....

Obinutuzumab plus lenalidomide...

11/09/2022

Oncology

Quiz

Quiz: Lenalidomide Plus Rituximab vs Rituximab Plus Chemotherapy in Patients With Follicular Lymphoma

11/09/2022

True or False: In a 6-year follow-up of the RELEVANCE trial, lenalidomide plus rituximab continued to demonstrate comparable efficacy and safety vs rituximab plus chemotherapy in patients with advanced-stage, previously untreated follicular...

True or False: In a 6-year...

11/09/2022

Oncology

Recent News

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma

05/16/2024

Amber Denham

The US Food and Drug...

05/16/2024

Oncology

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective...

05/08/2024

Oncology

FDA Approval

FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma

03/11/2024

Amber Denham

The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.

The FDA granted accelerated...

03/11/2024

Oncology

News

Prognostic Value of Minimal Residual Disease Among Previously Untreated Patients With Follicular Lymphoma

02/01/2024

Jordan Kadish

Minimal residual disease status...

02/01/2024

Oncology

News

Tisagenlecleucel Shows Comparable Efficacy, Superior Safety to Axicabtagene Ciloleucel Among Patients With R/R FL

01/22/2024

Amber Denham

Recent study results suggested...

01/22/2024

Oncology

News

Mosunetuzumab Yields Clinically Beneficial Outcomes for Patients With Follicular Lymphoma Treated With 3 or More Lines of Therapy

01/19/2024

Jordan Kadish

Real-world data indicated that...

01/19/2024

Oncology

News

Value of MAP Signature and M7-FLIPI for Identifying Risk and Outcomes for Patients With Follicular Lymphoma

01/15/2024

Jordan Kadish

Identifying specific gene...

01/15/2024

Oncology

News

Obinutuzumab Immunochemotherapy Yielded Sustained Improvement in Progression-Free Survival vs Rituximab Among Patients With FL

10/03/2023

Jordan Kadish

Final analysis of the phase 3...

10/03/2023

Oncology

News

Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Monotherapy for Patients With R/R Follicular Lymphoma

09/25/2023

Amber Denham

Zanubrutinib plus obinutuzumab demonstrated a favorable risk/benefit profile compared with obinutuzumab alone among patients with relapsed/refractory FL, according to results from a phase 2 trial.

Zanubrutinib plus obinutuzumab...

09/25/2023

Oncology

News

Prognostic Value of PET Status for Patients With R/R Follicular Lymphoma Undergoing AutoSCT

07/31/2023

Jordan Kadish

Pre-autologous stem cell...

07/31/2023

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology